• Journal of the Korean Society of Food Science and Nutrition
• /
• v.23 no.3
• /
• pp.472-480
• /
• 1994

Allicin was synthesized for the purpose of identification an dquantitation of a pharmaceutical dosage form in soft capsules. The identified transformed products fro allicin were dially disulfide , 3-vinyl-[4H]-1, 2-dithiin and 2-vinyl-[4H]-1, 3-dithiin in gas chromatrographic conditions and dially disulfide and ajoene in HPLC. Allicin is thermally unstable , it may be completely decomposed to vinyl dithiin isomers in GC conditions. For that reason, allicin was not found directly in the pharmaceutical dosage forms. In HPLC conditions, mobile phase was methanol /water containing 0.1% formic acid(65/35) and column was $\mu$-Bondapak C18. Detection wa-velength was 254nm. The retention time of allicin was 6.98min. The calibration ranger for allicin was 10 $\mu\textrm{g}$/ml to 200$\mu\textrm{g}$/ml and correlation coefficient(r) was 0.987.

• ALGAE
• /
• v.19 no.1
• /
• pp.59-68
• /
• 2004

Hizikia fusiformis hydroysates by five carbohydrases (Viscozyme, Celluclast, Termamyl and Ultraflo) and five proteases (Protamex, Kojizyme, Neutrase, Flavourzyme and Alcalase) were investigated for their extraction efficacy (yield and total total polyphenolic content) and antioxidative activity (DPPH radical and hydrogen peroxide scavenging activity). Termamyl and Ultraflo of the carbohydrases and Flavourzyme and Alcalase of proteases were selected by their high eficacy of extraction and antioxidative activity. Selected enzymes were used to investigate the optimum enzymatic reaction time and dosage (enzyme/substrate ratio) suitable for hydorolysis. Optimum reaction time for the enzymatic hydrolysis was 3 days and optimum dosage of hydrolysis was observed as 5%. Simultaneously, Ultraflo of the two carbohydrases and Alcalse of the two proteases were selected as the most effective enzymes. Combination of Ultraflo and Alcalase under optimum hydrolysis conditions could intensify the extraction efficacy of antioxidative materials form H. fusiformis. The hydrolysate obtained by combining the enzymes was separated into four different molecular weight fractions (<1kD, 1-10 kD, 10-30 kD and >30 kD) and recorded the polyphenolic content distribution and respective antioxidative ability. The fraction <1kD was identified as less effective and those fractions > 1kD indicated comparatively higher antioxidative activities related to their polyphenolic content.

• Biomolecules & Therapeutics
• /
• v.16 no.3
• /
• pp.210-214
• /
• 2008

The pharmacokinetic parameters and bioavailability of pranoprofen from the gel were measured to determine the enhancing effect of octanoic acid on the transdermal absorption of pranoprofen in rats. 8 mg/kg of pranoprofen was administered from gel with octanoic acid (the enhancer group) or that without octanoic acid (the control group) via the transdermal route, and the results were compared with those obtained from the intravenously (0.5 mg/kg, IV group) or orally administered group (4 mg/kg, oral group). The AUC of the control, the enhancer, the IV, and the oral groups were $20.2{\pm}5.1$, $50.7{\pm}12.7$, $19.9{\pm}2.5$, and $70.5{\pm}17.6\;ug/ml{\cdot}h$ respectively. The average $C_{max}$ of the control and the enhancer group were $0.93{\pm}0.23$ and $2.82{\pm}0.71\;ug/ml$, respectively, and the mean $T_{max}$ of the control and the enhancer group was 7.00 h. The relative bioavailability of the transdermally administered pranoprofen gel containing octanoic acid was approximately 2.50 times higher than the control group, showing a relatively constant, sustained blood concentration with minimal fluctuation. This suggests that it might be feasible to develop a pranoprofen gel preparation containing an enhancer for the transdermal administration, which is more convenient dosage form than the oral dosage forms.

• Journal of Pharmaceutical Investigation
• /
• v.31 no.3
• /
• pp.167-172
• /
• 2001

All-trans retinoic acid (ATRA), vitamin A acid, has been shown to exert anticancer activity in a number of types of cancers, particularly in acute promyelocytic leukaemia (APL). Due to its highly variable bioavailability and induction of its own metabolism after oral treatment, development of parenteral dosage forms are required. However, its poor aqueous solubility and chemical unstability give major drawbacks in parenteral administration. This study was undertaken to investigate a possibility to develop a parenteral formulation of ATRA by employing solid lipid nanoparticle (SLN) as a carrier. By optimizing the production parameters and the composition of SLNs, SLNs with desired mean particle size (<100 nm) as a parenteral dosage form could be produced from trimyristin (as solid lipid), Egg phosphatidylcholine and Tween 80 (as SLN stabilizer). The mean particle size of SLN formulation of ATRA was not changed during storage, suggesting its physical stability. Thermal analysis confirmed that the inner lipid core of SLNs exist at solid state. The mean particle size of ATRA-loaded SLNs was not significantly changed by the lyophilization process. ATRA could be efficiently loaded in SLNs, while maintaining its anticancer activity against HL-60, a well-known APL cell line. Furthermore, by lyophilization, ATRA loaded in SLN could be retained chemically stable during storage. Taken together, our present study demonstrates that physically and chemically stable ATRA formulation adequate for parenteral administration could be obtained by employing SLN technology.

• Proceedings of the Korean Environmental Health Society Conference
• /
• 2002.04a
• /
• pp.54-64
• /
• 2002

This study evaluated advanced water treatment (AWT) system in Korea. There are currently 16 plants operating with AWT. However, no attempt has been made to evaluate AWT system. This study selected one water treatment plant with AWT (pre-ozonation ＋ BAC). Using the operation data from 1995 to 2001 and pilot study results, the post-evaluation of the AWT system has been conducted. The study found that AWT improved water qualities of organic, ammonia, and turbidity, as expected. However, the extent of the improvement was generally short of the pilot study expectations. Pre-ozonation failed to decrease coagulant consumption. The dosage increased rather than decreased. AWT was, however, successful to decrease chlorine consumption. The chlorine reduction was related to the change in raw water characteristics and AWT introduction. Pre-ozonation failed to decrease coagulant consumption. The dosage increased rather than decreased. AWT was, however, successful to decrease chlorine consumption. The chlorine reduction was related to the change in raw water characteristics and AWT introduction, Both operation of pre-ozonation and reduced ammonia loading were responsible for the reduction. AWT increased the operation cost. Maintenance, raw water, and power cost increased, while labor and chemical cost decreased. Manpower reduction resulting form automation caused the decrease of labor cost. The reduction of chlorine consumption caused the decrease of chemical cost.

• Journal of Pharmaceutical Investigation
• /
• v.22 no.1
• /
• pp.49-54
• /
• 1992

This study was carried out for the purpose of developing an effective temazepam soft elastic gelatin capsule (softgel) which exhibits an excellent bioavailability and of comparing the rate and extent of absorption of temazepam from the marked elixir and prepared softgel using hydrophilic liquid such as polyethylene glycol 400 as a suspending agent by rotary die method. Both softgel and elixir containing 3 mg of temazepam were given to 7 healthy male New Zealand White rabbits in a single oral dose cross-over study. Plasma temazepam concentrations were measured by HPLC. The mean peak concentrations of temazepam following a single oral dosing as softgel and elixir dosage form were 13.84 and 13.25 ng/ml, respectively. And the mean time to peak concentration was 1.29 hr for the softgel and 1.07 hr for the elixir. There was no significant difference in the extent of drug absorption (AUC) for the two different dosage froms (p>0.05). While the softgel exhibited mean lag time of 0.63 hr, the elixir did not show any lag time. Statistical moment parameters such as the mean residence time and variance of the mean residence time did not differ significantly for the two formulations.

• Journal of Haehwa Medicine
• /
• v.10 no.1
• /
• pp.115-120
• /
• 2001

We came to the conclusion after considering all of information from many kinds of books on the Bufobufo gargarizans Cantor. The result were as follows: 1. Bufobufo gargarizans Cantor is originated from the bufonidae of caudata of amphibia of chordata. 2. The form of Bufobufo gargarizans Cantor is obese, about 12 centimeter long and the color of Bufobufo gargarizans Cantor is dark brown, black. 3. The charateristics and the tastes of Bufobufo gargarizans Cantor is cold and spicy and the Guigyung of Bufobufo gargarizans Cantor is heart and stomach. 4. The significant gredient of Bufobufo gargarizans Cantor is Bufagin, Steroids, Cinobufotoxin, ${\beta}$-sitosterol, Bufothionine, Bufotenidine, Bufo tenine, Bufalin, Butotalidin Hellebrigenin, Bufochrome. 5. The efficacy of Bufobufo gargarizans Cantor is pajinggyunhyul(破懲堅血), salgamjok(殺疳積), taehuyol(退虛熱), etc. 6. In direction of Bufobufo gargarizans Cantor, one time dosage is 2-3 gram in internal medicine, in external medicine dosage depends on the width. 7. Bufobufo gargarizans Cantor should be cautious in use those who is pregnant, have heart disease, gastritis, gastric ulcer. 8. The side effect of Bufobufo gargarizans Cantor is nausea, vomiting, abdomen discomfort, diarrhea, palpitation, headache, lethargy, etc. 9. Bufobufo gargarizans Cantor could be use in hepatoma, esophgeal cancer, stomach cancer, skin cancer, breast cancer and leukemia.

• Journal of Veterinary Science
• /
• v.23 no.2
• /
• pp.23.1-23.15
• /
• 2022

Background: Antibacterial agents play important roles in the treatment of bacterial infections. However, the development of antimicrobial resistance (AMR) and carry-over of substances into the environment are several problems arising during oral treatment of bacterial infections. We assessed AMR development in commensal Escherichia coli (E. coli) in enrofloxacin treated and untreated animals. In addition, we examined fluoroquinolone in the plasma and urine of treated and untreated animals, and in sedimentation dust and aerosol. Methods: In each trial, six pigs were treated with enrofloxacin via powder, granulate or pellet forms in two time periods (days 1-5 and 22-26). Four pigs served as untreated controls. The minimum inhibitory concentration (MIC) was determined to evaluate AMR development. Analysis of enro- and ciprofloxacin was performed with high performance liquid chromatography. Results: Non-wildtype E. coli (MIC > 0.125 ㎍/mL) was detected in the pellet treated group after the first treatment period, whereas in the other groups, non-wildtype isolates were found after the second treatment period. E. coli with MIC > 4 ㎍/mL was found in only the pellet trial. Untreated animals showed similar susceptibility shifts several days later. Bioavailability differed among the treatment forms (granulate > pellet > powder). Enro- and ciprofloxacin were detected in aerosols and sedimentation dust (granulate, powder > pellet). Conclusions: This study indicates that the kind of the oral dosage form of antibiotics affects environmental contamination and AMR development in commensal E. coli in treated and untreated pigs.

• Journal of Pharmaceutical Investigation
• /
• v.40 no.1
• /
• pp.15-21
• /
• 2010

Sibutramine is an orally administered centrally-acting antiobesity agent and inhibits both noradrenaline(norephinephirine) and serotonin(5-HT) reuptake. These effects are contributed by its active metabolites, M1 and M2. However, as the free base form of sibutramine is an oil form in room temperature, it had the problem of handling and stability. Thus, this drug should be used in the form of acid salt form in the pharmaceutical application. Unfortunately, anhydrous sibutramine hydrochloride is highly hygroscopic and unstable. In order to solve the hygroscopicity of the anhydrous salt form, another sibutramine acid salt form must be developed as a hydrate form. In this study. to overcome these problems, various of sibutramine acid salt forms were prepared with the pharmaceutically available salts such as maleate, esylate, mandelate, camsylate, besylate, salicylate, tartrate, isethionate and malate forms, and their physicochemical properties were investigated. Sibutramine malate was selected for excellent solubility and stability among the listed salt forms above. Its pharmacokinetic parameters were evaluated in rats comparing with sibutramine HCl, resulting in similar parameters. In vitro dissolution study of sibutramine malate-loaded capsule was performed comparison with commercial product ($Reductil^{(R)}$) in pH 1.2, pH 4.0, pH 6.8 and water medium. Our results indicated that there were no significant differences in their dissolution profiles were similar in all tested medium. Thus, sibutramine malate-loaded capsule should be a potential candiate due to its excellent solubility, good stability and biosimilar absorption.

• Archives of Pharmacal Research
• /
• v.26 no.12
• /
• pp.1002-1008
• /
• 2003

Ferulic acid (3-methoxy, 4-hydroxy cinnamic acid) is a flavoid component possessing antioxidant property. The compound is currently under development as a new drug candidate for the treatment of the dementia. The objective of this preformulation study was to determine the physicochemical properties of ferulic acid. The n-octanol to water partition coefficients of ferulic acid were 0.375 and 0.489 at the pHs of 3 and 10, respectively. Accelerated stability study for ferulic acid indicated that the t 90 value for the drug was estimated to be 459 days at $25^{\circ}C$. Ferulic acid was also found to be unstable under the relative humidity of more than 76%, probably because of the hygroscopic nature of the drug. In order to study compatibility of ferulic acid with typical excipients, potential change in differential scanning calorimetry spectrum was studied in 1: 1 binary mixtures of ferulic acid and typical pharmaceutical excipients (e.g., Aerosil, Avicel, CMC, Eudragit, lactose, PEG, PVP, starch and talc). Avicel, CMC, PVP and starch were found to be incompatible with ferulic acid, indicating the addition of these excipients may complicate the manufacturing of the formulation for the drug. Particle size distribution of ferulic acid powder was in the size range of 10-190 $\mu$m with the mean particle size of 61 $\mu$m. The flowability of ferulic acid was apparently inadequate, indicating the granulation may be necessary for the processing of the drug to solid dosage forms. Two polymorphic forms were obtained by recrystallization from various solvents used in formulation. New polymorphic form of ferulic acid, Form II, was obtained by recrystallization from 1,4-dioxane. The equilibrium solubility for Form I was approximately twice of that for Form II. The dissolution rate of Form II was higher than that of Form I in the early phase (<6 min). Therefore, these physicochemical information has to be taken in the consideration for the formulation of ferulic acid.